

this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Arnold, White & Durkee Deposit Account No. 01-2508/ARCD:177/WIM.

Reconsideration of the application is respectfully requested.

I. AMENDMENT

In the Specification:

On page 23 line 34, insert after "(mORK1)" the terms -- (SEQ ID NO:2) --
On page 23 line 35, insert after "(mORD1)" the terms -- (SEQ ID NO:4) --
On page 24 line 27, insert after "Intron 1" the terms -- (SEQ ID NO:12) --
On page 24 line 28, insert after "Intron 2" the terms -- (SEQ ID NO:11) --
On page 25 line 2, insert after "human kappa" the terms -- (SEQ ID NO:12) --
On page 25 line 2, insert after "(mORK1)" the terms -- (SEQ ID NO:2) --

In the Claims:

47. (Amended) A process of screening a substance for its ability to interact with an opioid receptor, said process comprising the steps of:

- a) providing a opioid receptor polypeptide wherein said opioid receptor polypeptide is selected from the group consisting of: (1) chimeric opioid receptors, (2) opioid receptor polypeptides including the amino acid sequence of SEQ ID NO:2 and (3) opioid receptor polypeptides including the sequence of SEQ ID NO:12;
- b) contacting said substance with the opioid receptor polypeptide; and
- [b]c) detecting [testing] the ability of said substance to interact with said opioid receptor.

49. (Amended) The process of claim 48, wherein one [the] polypeptide of the chimeric opioid receptor polypeptide comprises the second extracellular loop of delta opioid receptor.

50. (Amended) The process of claim 48, wherein one [the] polypeptide of the chimeric opioid receptor polypeptide comprises the third extracellular loop of delta opioid receptor.

51. (Amended) The process of claim 48, wherein the chimeric opioid receptor polypeptide comprises polypeptide portions of both kappa and delta opioid receptors.

59. (Amended) A process of isolating [making] a substance [product] with an ability to act as a specific agonist of a kappa opioid receptor, said process comprising the steps of:

- a) providing an opioid receptor polypeptide wherein said opioid receptor polypeptide is selected from the group consisting of: (1) chimeric opioid receptors, (2) opioid receptor polypeptides including the amino acid sequence of SEQ ID NO:2 and (3) opioid receptor polypeptides including the sequence of SEQ ID NO:12; [and]
- b) contacting [obtaining a] said opioid receptor polypeptide with a candidate substance [specific kappa opioid receptor agonist with said opioid receptor polypeptide]; and
- c) detecting [testing] the ability of said candidate substance to specifically interact as an agonist with [specific kappa opioid receptor agonist to interact with] said opioid receptor; and
- d) isolating said substance [providing a product that has] if the ability to interact with the opioid receptor is detected.

64. (Amended) The process of claim 63, wherein one [the] polypeptide of the chimeric opioid receptor polypeptide comprises the second extracellular loop of kappa opioid receptor.

65. (Amended) The process of claim 63, wherein one [the] polypeptide of the chimeric opioid receptor polypeptide comprises the third extracellular loop of delta opioid receptor.

New Claims:

Please add the following new claims by amendment:

-- 81. The process according to claim 47, wherein said opioid receptor polypeptide is a kappa opioid receptor polypeptide having the sequence of SEQ ID NO:2 or SEQ ID NO:12.

82. The process of claim 81, wherein said opioid receptor polypeptide is a kappa opioid receptor polypeptide encoded for by the polynucleotide of SEQ ID NO: 1.

83. The process of claim 81, wherein said opioid receptor polypeptide is a kappa opioid receptor polypeptide encoded for by the polynucleotide of SEQ ID NO: 11.

84. A process of screening a substance for its ability to interact with an opioid receptor, said process comprising the steps of:

BB

John C. F.

John D.

- a) providing a opioid receptor polypeptide wherein said opioid receptor polypeptide is encoded for by a polynucleotide comprising a base sequence that is identical or complementary to a segment of at least 40 contiguous bases of SEQ ID NO:1 or SEQ ID NO:11;
- b) contacting said substance with the opioid receptor polypeptide; and
- c) detecting the ability of said substance to interact with said opioid receptor.

85. The process of claim 84, wherein said polynucleotide comprises a base sequence that is identical or complementary to a segment of at least 40 contiguous bases of SEQ ID NO:1.

86. The process of claim 84, wherein said polynucleotide comprises a base sequence that is identical or complementary to a segment of at least 40 contiguous bases of SEQ ID NO:11.

87. The process of claim 84, wherein said polynucleotide comprises a base sequence that is identical or complementary to a segment of at least 55 contiguous bases of SEQ ID NO:1.